Day 2 - Wednesday 30th April 2025
12th Market Access, Pricing & Reimbursement Global Congress 2025 Europe
Comprehensive Strategies and Embracing Innovations to Overcome Barriers in Patient Access
Tuesday 29th - Wednesday 30th April 2025
Copthorne Tara Hotel London Kensington, London, UK
CHALLENGES AND OPPORTUNITIES
- Geopolitical drivers and access issues with high cost medicines
- Pharma alignment on value and issues with demonstrating value propositions
- Value based agreements and innovative contracting – real life cases from around the globe
- Access and reimbursement models for combo oncology, multiple indications and cell/gene therapies
Omar Ali, Visiting Lecturer, VBA & Former Advisor, NICE, University of Portsmouth
- Caregiver perspectives for different types of care
- Burden or QOL?
- A QALY is a QALY is a QALY – or is it?
Fleur Chandler, Patient Access Specialist, Chair, Project Hercules
- Present cases studies demonstrating how automated evidence synthesis tools support different phases of clinical development, from early evidence planning to reimbursement and post-market surveillance.
- Highlight how automation enhances decision-making and mitigates risks in market access by streamlining evidence generation and reducing redundancies.
- Examine the integration of human expertise with AI-driven solutions, showcasing how co-piloted automation enhances efficiency while maintaining strategic oversight.
Maria Rizzo, Senior Vice President, Evidence Synthesis, GIPAM GmbH
- Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to innovative therapies
- Why is the full stakeholder ecosystem important for gaining access in the future?
- How to Identify the stakeholder ecosystem for access success
- Step by step: Setting up a cross-functional program for access success
Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia
- Points of Discussion to follow shortly
Nazanin Mehin, Head of Global Market Access and Pricing for Immunology, Sanofi
- Points of Discussion to follow shortly
James Levine, President, Ipsen Foundation
- Traditional methods for determining rare genetic disease patient populations often underestimate the true figures due to reliance on reported patient numbers.
- Genetic database analysis provides a robust method to address these data gaps and determine more accurate estimates.
- HealthLumen applied these techniques to estimate the prevalence of late-onset Fabry disease. The findings suggest Fabry prevalence may be up to three times higher than current estimates, revealing a large undiagnosed and untreated population.
- This study demonstrates the power of genetic data to uncover hidden disease burden and help guide healthcare planning, policy, and therapeutic development for rare diseases.
Simon Lande, CEO and Co-founder, HealthLumen
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Moderator:
Catherine Akesson, Senior Consultant, Strategic Market Access, Congentia
Panellists:
